Ssurvey of augmentation of rivastigmine in combat post traumatic stress disorder

Survey of augmentation of rivastigmine in combat post traumatic stress disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211195280N10

Enrollment

Registered

2012-12-04

Start date

2009-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-traumatic stress disorder (PTSD). Post-traumatic stress disorder

Interventions

Intervention 1: rivastigmine 1.5 mg/ day two weeks and after two weeks increased 3mg/day Twice a day . Intervention 2: control group received placebo.

Treatment - Drugs

Placebo

rivastigmine 1.5 mg/ day two weeks and after two weeks increased 3mg/day Twice a day .

control group received placebo.

Eligibility

Sex/Gender

Male

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusions criteria: PTSD diagnosed based on DSM. IV-TR.military PTSD; MMSE score higher than 25. Exclusion criteria:Case refused . Rivastigmine side effects.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Symptoms of PTSD. Timepoint: at baseline and weeks 2, 4, 8, and 12. Method of measurement: PCL-M.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Rezaei Ardani

Mashhad University of medical sciences

rezaeia@mums.ac.ir+98 51 1711 2540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026